Evidence map›Paper›PMID 42495879›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

Tumor Profiling Using an NGS Cancer Hotspot Panel in Ukrainian Breast Cancer Patients: Initial Findings of Mutation Frequencies and Clinicopathologic Characteristics.

Roman Gulkovskyi, Liliia Fishchuk, Zoia Rossokha, Ganna Gerashchenko, Andrey Bezverkhiy, Volodymyr Kashuba, Olga Lobanova, Valeriy Cheshuk, Roman Vereshchako, Viktoriia Vershyhora and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Roman GulkovskyiDepartment of Molecular Oncogenetics, Institute of Molecular Biology and Genetics of the National Academy of Sciences of Ukraine, Kyiv, Ukraine.
Liliia FishchukExpert-Analytical Center of Molecular Genetics, Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine.ORCID 0000-0001-9999-7389
Zoia RossokhaExpert-Analytical Center of Molecular Genetics, Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine.
Ganna GerashchenkoDepartment of Molecular Oncogenetics, Institute of Molecular Biology and Genetics of the National Academy of Sciences of Ukraine, Kyiv, Ukraine.
Andrey BezverkhiyDepartment of Protein Biosynthesis Enzymology, Institute of Molecular Biology and Genetics of the National Academy of Sciences of Ukraine, Kyiv, Ukraine.
Volodymyr KashubaDepartment of Molecular Oncogenetics, Institute of Molecular Biology and Genetics of the National Academy of Sciences of Ukraine, Kyiv, Ukraine.
Olga LobanovaDepartment of Oncology, Bogomolets National Medical University, Kyiv, Ukraine.ORCID 0000-0003-1900-5816
Valeriy CheshukDepartment of Oncology, Bogomolets National Medical University, Kyiv, Ukraine.
Roman VereshchakoDepartment of Oncology, Bogomolets National Medical University, Kyiv, Ukraine.
Viktoriia VershyhoraExpert-Analytical Center of Molecular Genetics, Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine.
Olena PopovaExpert-Analytical Center of Molecular Genetics, Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine.
Natalia GorovenkoDepartment of Medical and Laboratory Genetics, Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine.
Zenoviy TkachukLaboratory of Innovative Biotechnologies, Department of Protein Biosynthesis Enzymology, Institute of Molecular Biology and Genetics of the National Academy of Sciences of Ukraine, Kyiv, Ukraine.
Mykhailo TukaloDepartment of Molecular Oncogenetics, Institute of Molecular Biology and Genetics of the National Academy of Sciences of Ukraine, Kyiv, Ukraine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundMolecular profiling with next-generation sequencing (NGS) can improve breast-cancer (BC) diagnostics, prognostication, and treatment selection. Despite this potential, tumor genomic testing has been insufficiently studied and implemented in Ukraine. This exploratory study aimed to identify and clinically analyze variants in tumor suppressor genes, oncogenes, as well as genes involved in epigenetic regulation and cellular signaling pathways, in tumor tissue samples from Ukrainian BC patients using NGS assessing a 50-gene targeted panel.MethodsThis was a retrospective cross-sectional study. Tumor tissue from 57 consecutively enrolled women with newly diagnosed, histologically confirmed BC was analyzed using the Ion AmpliSeq™ Cancer Hotspot Panel v2 (50 genes). Variants were filtered by stringent quality criteria and classified according to ACMG and AMP/ASCO/CAP. Group comparisons were evaluated using Fisher's exact and nonparametric tests; correlations were evaluated using Spearman's test.ResultsVariants were detected in 32 of 57 (56.1%) tumors across eight genes. The highest number of variants were detected in

Indexed as

Breast NeoplasmsHigh-Throughput Nucleotide SequencingAdultAgedBiomarkers, TumorCross-Sectional StudiesFemaleHumansMiddle AgedMutationRetrospective StudiesUkraineBiomarkers, Tumorbreast cancerhotspot panelNGSPIK3CATP53Ukraine

Identifiers

PMID42495879
PMCPMC13400919

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.